Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 11/2009

01-11-2009 | Original Article

Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack

Authors: Marcin Okroj, Leticia Corrales, Anna Stokowska, Ruben Pio, Anna M. Blom

Published in: Cancer Immunology, Immunotherapy | Issue 11/2009

Login to get access

Abstract

The complement system can be specifically targeted to tumor cells due to molecular changes on their surfaces that are recognized by complement directly or via naturally occurring antibodies. However, tumor cells often overexpress membrane-bound complement inhibitors protecting them from complement attack. We have previously shown that non-small cell lung cancer (NSCLC) cells, additionally to membrane-bound inhibitors, produce substantial amounts of soluble regulators such as factor I (FI) and factor H (FH). Since low oxygen concentration is associated with rapidly growing solid tumors, we studied how NSCLC cells protect themselves from complement attack under hypoxic conditions. Unexpectedly, mRNA levels and secretion of both FI and FH were significantly decreased already after 24 h exposure to hypoxia while cell viability measured by XTT assay and annexin V/7-AAD staining was affected only marginally. Furthermore, we observed decrease of mRNA level and loss of membrane-bound complement inhibitor CD46 and increased deposition of early (C3b) and terminal (C9) complement components on hypoxic NSCLC cells. All three complement pathways (classical, lectin and alternative) were employed to deposit C3b on cell surface. Taken together, our results imply that under hypoxic conditions NSCLC give up some of their available defense mechanisms and become more prone to complement attack.
Literature
2.
go back to reference Murdoch C, Giannoudis A, Lewis CE (2004) Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104(8):2224–2234PubMedCrossRef Murdoch C, Giannoudis A, Lewis CE (2004) Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104(8):2224–2234PubMedCrossRef
3.
go back to reference Brown JM, Giaccia AJ (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58(7):1408–1416PubMed Brown JM, Giaccia AJ (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 58(7):1408–1416PubMed
4.
go back to reference Greijer AE, van der Wall E (2004) The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 57(10):1009–1014PubMedCrossRef Greijer AE, van der Wall E (2004) The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 57(10):1009–1014PubMedCrossRef
5.
go back to reference Saikumar P, Dong Z, Patel Y, Hall K, Hopfer U, Weinberg JM, Venkatachalam MA (1998) Role of hypoxia-induced Bax translocation and cytochrome c release in reoxygenation injury. Oncogene 17(26):3401–3415PubMedCrossRef Saikumar P, Dong Z, Patel Y, Hall K, Hopfer U, Weinberg JM, Venkatachalam MA (1998) Role of hypoxia-induced Bax translocation and cytochrome c release in reoxygenation injury. Oncogene 17(26):3401–3415PubMedCrossRef
6.
go back to reference Swinson DE, Jones JL, Richardson D, Cox G, Edwards JG, O’Byrne KJ (2002) Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables. Lung Cancer 37(3):235–240PubMedCrossRef Swinson DE, Jones JL, Richardson D, Cox G, Edwards JG, O’Byrne KJ (2002) Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables. Lung Cancer 37(3):235–240PubMedCrossRef
7.
go back to reference Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379(6560):88–91PubMedCrossRef Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379(6560):88–91PubMedCrossRef
9.
go back to reference Jurianz K, Ziegler S, Garcia-Schuler H, Kraus S, Bohana-Kashtan O, Fishelson Z, Kirschfink M (1999) Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 36(13–14):929–939PubMedCrossRef Jurianz K, Ziegler S, Garcia-Schuler H, Kraus S, Bohana-Kashtan O, Fishelson Z, Kirschfink M (1999) Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 36(13–14):929–939PubMedCrossRef
10.
go back to reference Gorter A, Meri S (1999) Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today 20:576–582PubMedCrossRef Gorter A, Meri S (1999) Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today 20:576–582PubMedCrossRef
11.
go back to reference Ajona D, Castano Z, Garayoa M, Zudaire E, Pajares MJ, Martinez A, Cuttitta F, Montuenga LM, Pio R (2004) Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement. Cancer Res 64:6310–6318PubMedCrossRef Ajona D, Castano Z, Garayoa M, Zudaire E, Pajares MJ, Martinez A, Cuttitta F, Montuenga LM, Pio R (2004) Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement. Cancer Res 64:6310–6318PubMedCrossRef
12.
go back to reference Okroj M, Hsu YF, Ajona D, Pio R, Blom AM (2008) Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. Mol Immunol 45(1):169–179PubMedCrossRef Okroj M, Hsu YF, Ajona D, Pio R, Blom AM (2008) Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. Mol Immunol 45(1):169–179PubMedCrossRef
13.
go back to reference Ajona D, Hsu YF, Corrales L, Montuenga LM, Pio R (2007) Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth. J Immunol 178(9):5991–5998PubMed Ajona D, Hsu YF, Corrales L, Montuenga LM, Pio R (2007) Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth. J Immunol 178(9):5991–5998PubMed
14.
go back to reference Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC, Sotto JJ, Leroux D, Bensa JC, Plumas J (2003) In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 101(3):949–954PubMedCrossRef Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC, Sotto JJ, Leroux D, Bensa JC, Plumas J (2003) In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 101(3):949–954PubMedCrossRef
15.
go back to reference Stern M, Herrmann R (2005) Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol 54(1):11–29PubMedCrossRef Stern M, Herrmann R (2005) Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol 54(1):11–29PubMedCrossRef
16.
go back to reference Collard CD, Vakeva A, Bukusoglu C, Zund G, Sperati CJ, Colgan SP, Stahl GL (1997) Reoxygenation of hypoxic human umbilical vein endothelial cells activates the classic complement pathway. Circulation 96(1):326–333PubMed Collard CD, Vakeva A, Bukusoglu C, Zund G, Sperati CJ, Colgan SP, Stahl GL (1997) Reoxygenation of hypoxic human umbilical vein endothelial cells activates the classic complement pathway. Circulation 96(1):326–333PubMed
17.
go back to reference Collard CD, Bukusoglu C, Agah A, Colgan SP, Reenstra WR, Morgan BP, Stahl GL (1999) Hypoxia-induced expression of complement receptor type 1 (CR1, CD35) in human vascular endothelial cells. Am J Physiol 276(2 Pt 1):C450–C458PubMed Collard CD, Bukusoglu C, Agah A, Colgan SP, Reenstra WR, Morgan BP, Stahl GL (1999) Hypoxia-induced expression of complement receptor type 1 (CR1, CD35) in human vascular endothelial cells. Am J Physiol 276(2 Pt 1):C450–C458PubMed
18.
go back to reference Sharma RA, Dalgleish AG, Steward WP, O’Byrne KJ (2003) Angiogenesis and the immune response as targets for the prevention and treatment of colorectal cancer (review). Oncol Rep 10(5):1625–1631PubMed Sharma RA, Dalgleish AG, Steward WP, O’Byrne KJ (2003) Angiogenesis and the immune response as targets for the prevention and treatment of colorectal cancer (review). Oncol Rep 10(5):1625–1631PubMed
19.
20.
go back to reference Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR (1988) Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48(17):4827–4833PubMed Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR (1988) Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48(17):4827–4833PubMed
21.
go back to reference Li C, Jackson RM (2002) Reactive species mechanisms of cellular hypoxia-reoxygenation injury. Am J Physiol Cell Physiol 282(2):C227–C241PubMed Li C, Jackson RM (2002) Reactive species mechanisms of cellular hypoxia-reoxygenation injury. Am J Physiol Cell Physiol 282(2):C227–C241PubMed
22.
go back to reference Kannagi R (2007) Carbohydrate antigen sialyl Lewis a—its pathophysiological significance and induction mechanism in cancer progression. Chang Gung Med J 30(3):189–209PubMed Kannagi R (2007) Carbohydrate antigen sialyl Lewis a—its pathophysiological significance and induction mechanism in cancer progression. Chang Gung Med J 30(3):189–209PubMed
23.
go back to reference Ciurana CL, Zwart B, van Mierlo G, Hack CE (2004) Complement activation by necrotic cells in normal plasma environment compares to that by late apoptotic cells and involves predominantly IgM. Eur J Immunol 34(9):2609–2619PubMedCrossRef Ciurana CL, Zwart B, van Mierlo G, Hack CE (2004) Complement activation by necrotic cells in normal plasma environment compares to that by late apoptotic cells and involves predominantly IgM. Eur J Immunol 34(9):2609–2619PubMedCrossRef
25.
go back to reference Elward K, Griffiths M, Mizuno M, Harris CL, Neal JW, Morgan BP, Gasque P (2005) CD46 plays a key role in tailoring innate immune recognition of apoptotic and necrotic cells. J Biol Chem 280(43):36342–36354PubMedCrossRef Elward K, Griffiths M, Mizuno M, Harris CL, Neal JW, Morgan BP, Gasque P (2005) CD46 plays a key role in tailoring innate immune recognition of apoptotic and necrotic cells. J Biol Chem 280(43):36342–36354PubMedCrossRef
26.
go back to reference Trouw LA, Nilsson SC, Goncalves I, Landberg G, Blom AM (2005) C4b-binding protein binds to necrotic cells and DNA, limiting DNA release and inhibiting complement activation. J Exp Med 201(12):1937–1948PubMedCrossRef Trouw LA, Nilsson SC, Goncalves I, Landberg G, Blom AM (2005) C4b-binding protein binds to necrotic cells and DNA, limiting DNA release and inhibiting complement activation. J Exp Med 201(12):1937–1948PubMedCrossRef
27.
go back to reference Hakulinen J, Junnikkala S, Sorsa T, Meri S (2004) Complement inhibitor membrane cofactor protein (MCP; CD46) is constitutively shed from cancer cell membranes in vesicles and converted by a metalloproteinase to a functionally active soluble form. Eur J Immunol 34(9):2620–2629PubMedCrossRef Hakulinen J, Junnikkala S, Sorsa T, Meri S (2004) Complement inhibitor membrane cofactor protein (MCP; CD46) is constitutively shed from cancer cell membranes in vesicles and converted by a metalloproteinase to a functionally active soluble form. Eur J Immunol 34(9):2620–2629PubMedCrossRef
28.
go back to reference Budzko DB, Lachmann PJ, McConnell I (1976) Activation of the alternative complement pathway by lymphoblastoid cell lines derived from patients with Burkitt's lymphoma and infectious mononucleosis. Cell Immunol 22(1):98–109PubMedCrossRef Budzko DB, Lachmann PJ, McConnell I (1976) Activation of the alternative complement pathway by lymphoblastoid cell lines derived from patients with Burkitt's lymphoma and infectious mononucleosis. Cell Immunol 22(1):98–109PubMedCrossRef
29.
go back to reference Fujita T, Taira S, Kodama N, Matsushita M, Fujita T (1995) Mannose-binding protein recognizes glioma cells: in vitro analysis of complement activation on glioma cells via the lectin pathway. Jpn J Cancer Res 86(2):187–192PubMed Fujita T, Taira S, Kodama N, Matsushita M, Fujita T (1995) Mannose-binding protein recognizes glioma cells: in vitro analysis of complement activation on glioma cells via the lectin pathway. Jpn J Cancer Res 86(2):187–192PubMed
30.
go back to reference Gelderman KA, Kuppen PJ, Okada N, Fleuren GJ, Gorter A (2004) Tumor-specific inhibition of membrane-bound complement regulatory protein Crry with bispecific monoclonal antibodies prevents tumor outgrowth in a rat colorectal cancer lung. Cancer Res 64(12):4366–4372PubMedCrossRef Gelderman KA, Kuppen PJ, Okada N, Fleuren GJ, Gorter A (2004) Tumor-specific inhibition of membrane-bound complement regulatory protein Crry with bispecific monoclonal antibodies prevents tumor outgrowth in a rat colorectal cancer lung. Cancer Res 64(12):4366–4372PubMedCrossRef
31.
go back to reference Varela JC, Imai M, Atkinson C, Ohta R, Rapisardo M, Tomlinson S (2008) Modulation of protective T cell immunity by complement inhibitor expression on tumor cells. Cancer Res 68(16):6734–6742PubMedCrossRef Varela JC, Imai M, Atkinson C, Ohta R, Rapisardo M, Tomlinson S (2008) Modulation of protective T cell immunity by complement inhibitor expression on tumor cells. Cancer Res 68(16):6734–6742PubMedCrossRef
32.
go back to reference Angelo LS, Kurzrock R (2007) Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res 13(10):2825–2830PubMedCrossRef Angelo LS, Kurzrock R (2007) Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res 13(10):2825–2830PubMedCrossRef
33.
go back to reference Gately S, Li WW (2004) Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 31(2 Suppl 7):2–11PubMedCrossRef Gately S, Li WW (2004) Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 31(2 Suppl 7):2–11PubMedCrossRef
34.
go back to reference Leek RD, Harris AL (2002) Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia 7(2):177–189PubMedCrossRef Leek RD, Harris AL (2002) Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia 7(2):177–189PubMedCrossRef
Metadata
Title
Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack
Authors
Marcin Okroj
Leticia Corrales
Anna Stokowska
Ruben Pio
Anna M. Blom
Publication date
01-11-2009
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 11/2009
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-009-0685-8

Other articles of this Issue 11/2009

Cancer Immunology, Immunotherapy 11/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine